NCT05774639 - Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria | Biotech Hunter

Enrollment

600

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

October 3, 2024

Study Completion Date

December 31, 2024

Conditions

Chronic Idiopathic Urticaria

Interventions

DRUG

Omalizumab Injection

ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)

DRUG

Xolair Prefilled Syringe

XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution

Trial Locations (6)

San Marcus research Clinic, Inc, Miami Lakes

True Blue Clinical Research, Brandon

Access Research Institute, Brooksville

Options Research Group, West Lafayette

Site 001, Mumbai

Al Essra Hospital, Amman